Condition: Acute Myeloid Leukemia · Sponsor: Technische Universität Dresden
This phase II clinical trial evaluates the efficacy and tolerability of the non-intensive treatment with venetoclax and the hypomethylating agent azacitidine as compared to the standard of care chemotherapy plus gemtuzumab ozogamicin in newly diagnosed NPM1 mutated AML patients fit for intensive chemotherapy.
This description comes directly from the study's public registry record.
Manja Reimann, Dr. · +49 351 458 · vincent@ukdd.de
Frank Fiebig · +49 351 458 · vincent@ukdd.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Essen | Essen, North Rhine-Westphalia, Germany | Recruiting |
| Universitätsklinikum Aachen | Aachen, Germany | Recruiting |
| Universitätsklinikum Augsburg | Augsburg, Germany | Recruiting |
| Klinikum Chemnitz gGmbH | Chemnitz, Germany | Recruiting |
| Universiätsklinikum Köln | Cologne, Germany | Not Yet Recruiting |
| Universitätsklinikum Dresden | Dresden, Germany | Recruiting |
| Universitätsklinikum Erlangen | Erlangen, Germany | Recruiting |
| Johann Wolfgang Goethe-Universität | Frankfurt am Main, Germany | Recruiting |
| Universitätsklinikum Halle | Halle, Germany | Recruiting |
| Universitätsklinikum Heidelberg | Heidelberg, Germany | Recruiting |
| Universitätsklinikum Schleswig-Holstein | Kiel, Germany | Recruiting |
| Universitätsklinikum Leipzig | Leipzig, Germany | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05904106